Abstract: It discloses an ophthalmic pharmaceutical preparation as well as a preparation method and application thereof. Components of the pharmaceutical preparation are easy to obtain and are from a panax notoginseng extract. The pharmaceutical preparation is a natural traditional Chinese medicine preparation and contains the following components with a total of 45 to 95%: a notoginsenoside R1, a notoginsenoside R2, a ginsenoside Rg1, a ginsenoside Rg2, a ginsenoside Re, a ginsenoside Rb1, a ginsenoside Rb2, a ginsenoside Rd, a ginsenoside Rf, a ginsenoside Rc, a ginsenoside Rh1 and a gypenoside IX. The extract can be made into eye drops, eye ointments, eye pads, eye cream and other various dosage forms according to clinical demands.

Abstract: The present disclosure discloses an inhibitor for abnormal lipid metabolism of tumor cells with a plant cyclopeptide as an effective component, and discloses application of the inhibitor to preparation of drugs for inhibiting abnormal lipid metabolism of the tumor cells, which specifically can be applied to preparation of drugs for treating and preventing abnormal lipid metabolism related cancers including liver cancer, colon cancer, rectal cancer and prostatic cancer. The inhibitor for abnormal lipid metabolism of the cells of the present disclosure can effectively inhibit abnormal lipid metabolism of the tumor cells. Its effective component, the plant cyclopeptide, is wide in source and mature in extraction technology. The inhibitor has diversified dosage forms and medication ways and has a wide clinical application prospect.

Abstract: A cell autophagy inhibitor using a rubiaceae-type cyclopeptide as the active ingredient, and is particularly used for inhibiting KRAS mutation, especially protective autophagy of KRAS dependent tumor cells, and promoting tumor cell apoptosis; the inhibitor is preferably a nano-micelle injection, which can be used to the preparation of a medicament for treating and preventing KRAS-related cancers including colon cancer, rectal cancer, lung cancer and pancreatic cancer. The cell autophagy inhibitor of the present invention can effectively inhibit the protective autophagy of tumor cells, and its active ingredient rubiaceae-type cyclopeptides have a wide range of sources, mature extraction processes, diversified dosage forms and administration methods, and can be used to the treatment and prevention of KRAS-related cancers and have broad clinical application prospects.

Abstract: The disclosure relates to application of a compositae type cyclopeptide compound or a pharmacologically permissible salt as a cGAS-STING signal channel inhibitor and application of the compositae type cyclopeptide compound or the pharmacologically permissible salt as the cGAS-STING signal channel inhibitor in preparing a drug for treating diseases caused by abnormal activation of a cGAS-STING signal channel. As the compositae type cyclopeptide compound is a natural compound diversified in dosage form and medication mode, the compositae type cyclopeptide compound has a wide clinical application prospect.